Prognostic value of vascular endothelial growth factor expression in patients with prostate cancer: A systematic review with meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 11, 2012, Pages 5665-5669

  Wang, Kai ^a   Peng, Hong Ling ^b   Li, Long Kun ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Meta analysis; Prognosis; Prostate cancer; Vascular endothelial growth factor

Indexed keywords

EID: 84874059203     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.11.5665     Document Type: Article

References (35)

1. Banerjee S, Dowsett M, Ashworth A, Martin LA (2007). Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol, 4, 536-50.
2. Barraclough H, Simms L, Govindan R (2011). Biostatistics primer: what a clinician ought to know: hazard ratios. J Thorac Oncol, 6, 978-82.
3. Bates DO, Lodwick D, Williams B (1999). Vascular endothelial growth factor and microvascular permeability. Microcirculation, 6, 83-96.
4. Bok RA, Halabi S, Fei DT, et al (2001). Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res, 61, 2533-6.
5. Brawley OW (2012). Prostate cancer epidemiology in the United States. World J Urol, 30, 195-200.
6. Caine GJ, Lip GY, Stonelake PS, Ryan P, Blann AD (2004). Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost, 92, 185-90.
7. Carmeliet P, Jain RK (2011). Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov, 10, 417-27.
8. Duque JL, Loughlin KR, Adam RM, et al (1999). Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology, 54, 523-7.
9. Fong GH, Rossant J, Gertsenstein M, Breitman ML (1995). Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature, 376, 66-70.
10. Fukuda H, Tsuchiya N, Narita S, et al (2007). Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer. Oncol Rep, 18, 1155-63.
11. George DJ, Halabi S, Shepard TF, et al (2001). Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res, 7, 1932-6.
12. Green MM, Hiley CT, Shanks JH, et al (2007). Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys, 67, 84-90.
13. Jain L, Vargo CA, Danesi R, et al (2009). The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther, 8, 2496- 508.
14. Kaban K, Herbst RS (2002). Angiogenesis as a target for cancer therapy. Hematol Oncol Clin North Am, 16, 1125-71.
15. Kelly WK, Halabi S, Carducci M, et al (2012). Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol, 30, 1534-40.
16. Kowanetz M, Ferrara N (2006). Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res, 12, 5018-22.
17. Kuniyasu H, Troncoso P, Johnston D, et al (2000). Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res, 6, 2295-308.
18. Martin B, Paesmans M, Mascaux C, et al (2004). Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer, 91, 2018-25.
19. Mori R, Dorff TB, Xiong S, et al (2010). The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. Prostate, 70, 1692-700.
20. Nassif AE, Tambara Filho R, Paula RX, Taguchi WS, Pozzobon HJ (2009). [Epidemiologic profile and prognostic factors in clinically localized prostate adenocarcinoma submitted to surgical treatment]. Rev Col Bras Cir, 36, 327-31.
21. Peyromaure M, Camparo P, Badoual C, Descazeaud A, Dinh- Xuan AT (2007). The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy. BJU Int, 99, 1150-3.
22. Pili R, Rosenthal MA, Mainwaring PN, et al (2010). Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res, 16, 2906-14.
23. Pradeep CR, Sunila ES, Kuttan G (2005). Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Integr Cancer Ther, 4, 315-21.
24. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ (2004). Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol, 172, 910-4.
25. Ross RW, Galsky MD, Febbo P, et al (2012). Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer : A Prostate Cancer Clinical Trials Consortium trial. Cancer, 118, 4777-84.
26. Shariat SF, Anwuri VA, Lamb DJ, et al (2004). Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol, 22, 1655-63.
27. Shariat SF, Karam JA, Walz J, et al (2008). Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res, 14, 3785-91.
28. Shijubo N, Kojima H, Nagata M, et al (2003). Tumor angiogenesis of non-small cell lung cancer. Microsc Res Tech, 60, 186-98.
29. Sitohy B, Nagy JA, Dvorak HF (2012). Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res, 72, 1909-14.
30. Svatek RS, Jeldres C, Karakiewicz PI, et al (2009). Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate, 69, 886-94.
31. Wang Q, Diao X, Sun J, Chen Z (2011). Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy. Urol Oncol.
32. Weber DC, Tille JC, Combescure C, et al (2012). The prognostic value of expression of HIF1alpha, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy. Radiat Oncol, 7, 66.
33. West AF, O'Donnell M, Charlton RG, Neal DE, Leung HY (2001). Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br J Cancer, 85, 576-83.
34. Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985). Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis, 27, 335-71.
35. Zilinberg K, Roosen A, Belka C, Ganswindt U, Stief CG (2012). [Management of prostate cancer]. MMW Fortschr Med, 154, 47-50.